Ramesh Gihwala, MD
Psychiatry · Gastonia, NCNPI 1447200183
Payments from drug & device makers
Across 1,597 payments — averaging $341.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$275K
- Teva Pharmaceuticals USA, Inc.$173K
- Vanda Pharmaceuticals Inc.$57K
- Otsuka America Pharmaceutical, Inc.$19K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$10K
- Alkermes, Inc.$3K
- plus $8K from 15 others
What the payments were for
- Consulting fees$1,8100%
- Speaking & faculty fees$482,78289%
- Travel & lodging$33,9616%
- Food & beverage$26,1655%
- Education$3620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 478 | $275,107 |
| Teva Pharmaceuticals USA, Inc. | 306 | $173,208 |
| Vanda Pharmaceuticals Inc. | 142 | $56,875 |
| Otsuka America Pharmaceutical, Inc. | 92 | $19,278 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 106 | $10,043 |
| Alkermes, Inc. | 66 | $2,696 |
| Neurocrine Biosciences, Inc. | 107 | $1,866 |
| Sunovion Pharmaceuticals Inc. | 83 | $1,537 |
| Johnson & Johnson | 42 | $1,000 |
| Axsome Therapeutics, Inc. | 15 | $549 |
| Indivior Inc. | 28 | $499 |
| E.r. Squibb & Sons, L.L.C. | 19 | $460 |
| Idorsia Pharmaceuticals US Inc | 15 | $362 |
| Neos Therapeutics, LP | 27 | $344 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $319 |
| Lundbeck LLC | 17 | $305 |
| Avanir Pharmaceuticals, Inc. | 15 | $250 |
| Noven Therapeutics, LLC | 9 | $153 |
| Supernus Pharmaceuticals, Inc. | 7 | $137 |
| Merck | 3 | $48 |
| Eisai Inc. | 3 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$266,989
- UZEDY$114,923
- Fanapt$55,120
- Austedo XR$39,153
- ABILIFY MAINTENA$17,554
- AUSTEDO$11,535
- ABILIFY ASIMTUFII$11,109
- CAPLYTA$8,540
- ARISTADA$5,900
- ARISTADA INITIO$1,475
- INGREZZA$373
- Auvelity$236
- SPRAVATO$125
- QUVIVIQ$125
- LATUDA$121
- REXULTI$109
How this compares
$545,079 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 28 | $289,112 |
| VraylarCariprazine Hcl | 195 | $287,544 |
| IngrezzaValbenazine Tosylate | 29 | $249,623 |
| UzedyRisperidone | 51 | $168,227 |
| FanaptIloperidone | 75 | $150,684 |
| CaplytaLumateperone Tosylate | 43 | $76,969 |
| RexultiBrexpiprazole | 48 | $71,013 |
| TrintellixVortioxetine Hydrobromide | 75 | $40,762 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $29,026 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $16,530 |
| Clozapine | 154 | $12,551 |
| QuviviqDaridorexant Hcl | 17 | $9,041 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 89 | $8,789 |
| Lurasidone Hcl | 83 | $6,594 |
| Paliperidone ErPaliperidone | 33 | $5,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $173,208 | $457,33979 claims |
| AbbVieVraylar | $275,107 | $287,544195 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,866 | $249,62329 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $56,875 | $150,68475 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $10,043 | $76,96943 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $19,278 | $71,01348 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $319 | $40,76275 claims |
| Alkermes, Inc.Lybalvi | $2,696 | $29,02619 claims |
| Axsome Therapeutics, Inc.Auvelity | $549 | $16,53013 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $362 | $9,04117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Gastonia
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
- Oleg TcheremissineCharlotte$2M
- Richard WeislerRaleigh$1.2M
- Dan BlazerDurham$1M
- Samantha Meltzer-BrodyChapel Hill$909K
- Andrew KrystalDurham$754K
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.